about
The development of bispecific antibodies and their applications in tumor immune escape.Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.Antibodies to watch in 2017Current progress in innovative engineered antibodies.Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab.Platelet-Targeted Delivery of Peripheral Blood Mononuclear Cells to the Ischemic Heart Restores Cardiac Function after Ischemia-Reperfusion InjuryRecombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.Protein purification and analysis: next generation Western blotting techniques.Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.Bispecific Antibody Process Development: Assembly and Purification of Knob and Hole Bispecific Antibodies.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies.Redirecting T cells to hematological malignancies with bispecific antibodies.Bispecific antibodies: design, therapy, perspectives.Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies.Aligning physics and physiology: Engineering antibodies for radionuclide delivery.Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment.A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity.Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody.Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.Site-Specific Antibody Conjugation for ADC and Beyond.Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion.An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.A bi-specific inhibitor targeting IL-17A and MMP-9 reduces invasion and motility in MDA-MB-231 cells.Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer TherapyBispecific antibodies in cancer immunotherapyA bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicityBi-specific and tri-specific antibodies- the next big thing in solid tumor therapeuticsEngineering multi-specific antibodies against HIV-1Expanding the Boundaries of Biotherapeutics with Bispecific AntibodiesDesign, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells
P2860
Q33630292-DB5EAFD8-BECE-4B14-815E-D9DB7B891C51Q37631316-39DA37BD-151C-4D28-BFB4-3782C590085BQ37631319-743604A8-9865-4A3C-8287-59B93F825761Q40077818-BFAE027D-DF72-419B-B59A-267183DE0F3DQ40407506-47BCA9DD-9C1F-45C4-BE67-9D58397C1D06Q41149154-74456753-8254-429D-939A-F178F0382DC0Q41240124-F00119FB-8AC9-4352-9BBB-DFF1F5F07777Q42660142-FD7ACF56-0047-462E-A7C8-3CB2CCC7A172Q45037117-3D62DA9D-1E49-4977-9FDC-AFF4474124ECQ46338913-57E109E9-DFC5-4A9E-99DA-134C3B47F9FAQ47099672-8CF3072D-A268-491D-91D9-E18768F72CFCQ47138591-27048E8A-4157-4484-866B-C811C37D5165Q47342853-EB3809DE-2751-43CC-A435-357E315CBC4FQ47570404-35FD6015-966D-4090-9AE2-D036D2852371Q47597795-48F77F0D-350B-4E83-9547-B4825308107FQ48339827-DAE7E4D0-A8A8-4295-B841-B896E65576F5Q49195146-24FFEA60-F842-465B-8736-5E72C2540B22Q49592680-3EED49A6-DCE8-48FC-9D71-B9483E3A6315Q49951608-0553BBC1-07AE-4CB2-A866-B6E503D3953EQ51740406-5731AEF6-DE71-4EA4-AA2A-D1793CBC6FDDQ52362264-1F3B9583-9C08-4D5A-BCEB-EEFA2DE81D7EQ52372561-8CDAA710-464E-433F-8A7E-D69D16B81D56Q52579768-94BCC6E6-9EB6-4AB9-9C68-3FC42A2CFF31Q52723685-0795C628-0C67-472D-9CD1-3CD8029CDC02Q52731744-C6CD8170-DCB0-4151-9BAB-C2CACE393494Q55022669-7AB6F124-06B5-4453-9F07-9B4DE7DAD58FQ55240690-72A646A1-9A3B-43AA-9B8A-83C444C839A9Q55354182-19A2B2EC-6FF8-4F16-A073-F77315D0594BQ55413334-41D42BEB-6B9D-40E0-A933-9C84AD8B09D9Q55439903-A47C3A86-1149-4A7A-B128-EE5111F36BA2Q55504448-14582431-E142-46EF-B807-A7827C4E8A8DQ56890857-A918E3F3-CC62-4277-9D3A-F90BBE28E8F3Q56893015-41FD2A97-C0C4-4880-AB8D-6A7582664A28Q57061905-9C26D6EC-A966-4B11-8D99-8967FE6B5F5FQ57151874-44FC61CE-4849-4C27-9C2C-D13859E4FAEBQ58696428-E9C9691C-6939-40BC-8179-2A48B1A019EBQ58724935-6FF301A4-3FDF-4524-85C5-801134D3439FQ59134014-5A050BC1-6D2B-4273-840E-3C0BC7CC84D7
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
The making of bispecific antibodies
@en
The making of bispecific antibodies
@nl
type
label
The making of bispecific antibodies
@en
The making of bispecific antibodies
@nl
prefLabel
The making of bispecific antibodies
@en
The making of bispecific antibodies
@nl
P2860
P921
P1476
The making of bispecific antibodies
@en
P2093
Roland E Kontermann
Ulrich Brinkmann
P2860
P304
P356
10.1080/19420862.2016.1268307
P577
2017-01-10T00:00:00Z